{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:16:10Z","timestamp":1770905770525,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40123-025-01299-5","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:42:14Z","timestamp":1769193734000},"page":"803-816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase\u00a0III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea\u00ae in Patients with Wet Age-Related Macular Degeneration"],"prefix":"10.1007","volume":"15","author":[{"given":"Mudit","family":"Bansal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit Sanjay","family":"Laul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmil","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajpal","family":"Vohra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shachi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharad","family":"Bhomaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourabh","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishri Murli","family":"Manoher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Sapar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Parwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay Kartik","family":"Amabde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sribhargava","family":"Natesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupak Kanti","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lional Raj","family":"D","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibhuti P.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minija","family":"C K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekta","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod","family":"Bhende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritesh","family":"Narula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandana","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh","family":"Bathula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhargav","family":"Darji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maulik","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"2","key":"1299_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"1299_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","volume":"117","author":"R Kawasaki","year":"2010","unstructured":"Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921\u20137.","journal-title":"Ophthalmology"},{"issue":"2","key":"1299_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70163-3","volume":"2","author":"JB Jonas","year":"2014","unstructured":"Jonas JB. Global prevalence of age-related macular degeneration. Lancet Glob Health. 2014;2(2):65e66.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"1299_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.03.1041","volume":"18","author":"N Likhar","year":"2015","unstructured":"Likhar N, Mothe RK, Kanukula R, Shah C, Dang A. The prevalence of age-related macular degeneration in Indian population: a systematic review. Value Health. 2015;18(3):A180.","journal-title":"Value Health"},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.envres.2014.05.023","volume":"133","author":"EW Wu","year":"2014","unstructured":"Wu EW, Schaumberg DA, Park SK. Environmental cadmium and lead exposures and age-related macular degeneration in U.S. adults: the National Health and Nutrition Examination Survey 2005 to 2008. Environ Res. 2014;133:178\u201384.","journal-title":"Environ Res"},{"issue":"4","key":"1299_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2147\/ciia.2006.1.4.451","volume":"1","author":"TE Kenneth","year":"2006","unstructured":"Kenneth TE, Kertes PJ. Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging. 2006;1(4):451\u201366.","journal-title":"Clin Interv Aging"},{"issue":"9","key":"1299_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","volume":"96","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. Aflibercept (VEGF trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96(9):1157\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1299_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137(4):372\u20139.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1299_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jamaophthalmol.2019.1971","volume":"137","author":"ST Berkowitz","year":"2019","unstructured":"Berkowitz ST, Sternberg P, Feng X, Chen Q, Patel S. Analysis of anti\u2013vascular endothelial growth factor injection claims data in US medicare part B beneficiaries from 2012 to 2015. JAMA Ophthalmol. 2019;137(8):921\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1299_CR10","unstructured":"Prescribing information of Eylea\u00ae (Aflibercept) Injection, for intravitreal use. Revised 03\/2021, Manufactured by: Regeneron Pharmaceuticals, Inc."},{"issue":"17","key":"1299_CR11","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1299_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis"},{"issue":"5","key":"1299_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41433-023-02813-4","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma A, Loewenstein A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Aflibercept biosimilars\u2013update on the development progress. Eye. 2024;38(5):824\u20135.","journal-title":"Eye"},{"issue":"12","key":"1299_CR14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"7","key":"1299_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Bradvica M, Vajas A, et al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase\u00a03 randomized clinical trial. JAMA Ophthalmol. 2023;141(7):668\u201376.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.4103\/ijo.IJO_2118_21","volume":"70","author":"R Singh","year":"2022","unstructured":"Singh R, Chauhan R, Saxena A, et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin\u2019s ranibizumab with Lucentis\u00ae in patients with neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70(8):3008\u201314.","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"1299_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40123-024-00883-5","volume":"13","author":"AK Ghosh","year":"2024","unstructured":"Ghosh AK, Nikumbh US, Shukla CK, et al. Efficacy, safety and immunogenicity of sun\u2019s ranibizumab biosimilar in neovascular age-related macular degeneration: a phase\u00a03, double-blind comparative study. Ophthalmol Ther. 2024;13(5):1369\u201382.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1299_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40123-023-00836-4","volume":"13","author":"B Li","year":"2024","unstructured":"Li B, Fan K, Zhang T, et al. Efficacy and safety of biosimilar QL1207 vs. the reference aflibercept for patients with neovascular age-related macular degeneration: a randomized phase\u00a03 trial. Ophthalmol Ther. 2024;13(1):353\u201366.","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01299-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:26:30Z","timestamp":1770902790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01299-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01299-5","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Deven Parmar is an employee of Zydus Therapeutics Inc., USA. Lokesh Bathula, Sandip Kirtane, Bhargav Darji, and Maulik Doshi are employees of Zydus Lifesciences Ltd. Mudit Bansal, Punit Singh, Ruchi K Mehta, Rohit Sanjay Laul, Parth Rana, Urmil Shah, Rajpal Vohra, Shachi Desai, Sharad Bhomaj, Sourabh Patwardhan, Jaishri Murli Manoher, Anjali Sapar, Sandeep Parwal, Ajay Kartik Amabde, Rahul Shroff, Sribhargava Natesh, Rupak Kanti Biswas, Lional Raj D, Bibhuti P Sinha, Minija C K, Ekta Patel, Ashish Kamble, Pramod Bhende, Sandeep Patil, Anup Shah, Ritesh Narula, and Bandana Kumari have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was duly approved by the institutional ethics committees (IECs) of the respective study sites and by the Central Drugs Standard Control Organization (CDSCO), in compliance with the New Drugs and Clinical Trials Rules, 2019. A detailed list of study sites along with their respective IECs is provided in the Supplementary Material. The study was conducted in accordance with the ethical principles of Declaration of Helsinki, Good Clinical Practice (GCP) guidelines of CDSCO, Ethical guidelines for Biomedical Research on Human Participants by the Indian Council of Medical Research (ICMR), and other relevant regulatory guidelines. Written informed consent was obtained from all participants prior to enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}